Le Lézard
Classified in: Health
Subject: SVY

Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals


Vendors that provide services instead of just being a supplier of devices to enjoy greater growth opportunities, finds Frost & Sullivan

SANTA CLARA, Calif., Oct. 21, 2019 /PRNewswire/ -- The rise of targeted therapy and drug compounds is prompting the development of novel drug delivery approaches such as nano gel and transdermal patches. Although intravenous (IV) infusion continues to dominate the market, subcutaneous, intradermal, and intramuscular modes will gain significant traction in five to eight years, when approximately 30 to 35 new products will be launched. Digital transformation will especially play a role in driving the $88.2 billion market in 2018 toward a $125 billion market by 2023, at a compound annual growth rate of approximately 7.2%.

Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals

"With the availability of multiple home care devices, drug delivery device makers are looking to invest in technologies that support sensors and apps to monitor out-of-clinical settings. Solutions that offer a predictability and wellness index for efficient patient flow will find significant adoption among hospitals," said Bejoy Daniel, Senior Industry Analyst, Transformational Health. "Acknowledging the potential of digital solutions, vendors are focused on analyzing the available data and enabling connectivity to integrate devices."

Frost & Sullivan's recent analysis, Analysis of the Drug Delivery Devices Market, Forecast to 2023, examines the investment opportunities for companies in the drug delivery market. It covers the product segments of pulmonary, injectable, and transdermal drug delivery devices in the traditional clinical and home care settings. The study highlights the trends in the US and the EU5 (France, Germany, Italy, Spain, and the UK).

For further information on this analysis, please visit: http://frost.ly/3ud.

"At $49.6 billion, the US market accounted for 56.3% of the revenues of the total market in 2018. Europe was not far behind due to its lead in the pulmonary device segment," noted Daniel. "Germany and the United Kingdom dominated the European market as they had witnessed rapid technological innovations in drug delivery technologies."

Despite the advances in the field of drug delivery, there are several unmet patient needs. Vendors can find ample growth opportunities through:

Analysis of the Drug Delivery Devices Market, Forecast to 2023 is part of Frost & Sullivan's global Advanced Medical Technologies Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Analysis of the Drug Delivery Devices Market, Forecast to 2023
ME91-54

Contact:
Mariana Fernandez
Corporate Communications
T: +1 210 348 10 12
E: Mariana.Fernandez@frost.com

http://ww2.frost.com

SOURCE Frost & Sullivan


These press releases may also interest you

at 02:17
Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the...

at 02:17
Orexo AB (publ.), (STO: ORX) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of opioid overdose. The US...

at 02:11
BioArctic AB (publ) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer's disease. The antibodies target a...

at 02:05
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short will be responsible for...

at 01:21
JANUARY 1 - DECEMBER 31, 2020 (compared with the corresponding period a year ago) Highest adjusted EBITA and highest adjusted EBITA margin everTarget raised for adjusted return on capital employed to above 17% by 2025Net sales declined 5.6% to SEK...

at 01:00
Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus...



News published on 21 october 2019 at 11:34 and distributed by: